EDAP Significantly Strengthens Financial Profile

EDAP Significantly Strengthens Financial Profile

  Closes $12.0 Million Placement to Fully Redeem $8.0 Million Long-Term Debt

         Positions Company to Invest in Expansion of U.S. Operations

LYON, France, May 29, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a
global leader in therapeutic ultrasound, outlined today the strengthening of
its financial profile with the closing of a $12.0 million registered direct
placement of ordinary shares in the form of American Depositary Shares, at a
price of $4.00 per share, with warrants attached. The Company intends to fully
redeem its $8.0 million outstanding long-term debt by using a portion of the
net proceeds from the offering. The expected debt repayment eliminates the 9%
annual interest paid quarterly in either shares or cash, and removes the
redemption obligation ahead of the June 2014 maturity. EDAP intends to utilize
the remaining net proceeds balance to invest in the expansion of its U.S.
operations in preparation of potential approval of its Ablatherm-HIFU for the
treatment localized prostate cancer as the Pre-Market Approval (PMA)
application is currently under review by U.S. FDA.

Marc Oczachowski, Chief Executive Officer, commented, "This offering
streamlines our balance sheet by enabling the early repayment of the long-term
debt and is significant news for the Company and its shareholders.
Additionally, the funds provide expansion capital for our U.S. operations as
we continue to advance the PMA application for our Ablatherm-HIFU device.We
are particularly satisfied with the participation in the offering by existing
shareholders and historical investors as it underscores their belief in our
long term business strategy both in the U.S. and around the globe. EDAP is now
positioned to leverage its potential milestones for commercial success."

H.C. Wainwright & Co., LLC, acted as the exclusive placement agent for the
transaction.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low occurrence of
side effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for surgery or
who prefer an alternative option, or for patients who failed radiotherapy
treatment., Ablatherm-HIFUis approved and commercialized in Europe as a
treatment for prostate cancer and is currently under regulatory review in the
U.S. following submission of the Pre-Market Approval Application in February
2013 after the completion ofa multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA. The
Company also develops its HIFU technology for the potential treatment of
certain other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL). For more information on
the Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. Such
statements are based on management's current expectations and are subject to a
number of uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ materially from
those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission and in
particular, in the sections "Cautionary Statement on Forward-Looking
Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or
marketed in the United States.

CONTACT: Blandine Confort
         Investor Relations / Legal Affairs
         EDAP TMS SA
         +33 4 72 15 31 72
         bconfort@edap-tms.com
        
         Investors:
         Stephanie Carrington
         The Ruth Group
         646-536-7017
         scarrington@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.